China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal
29/05/2026 24:15
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal May 29 (Reuters) - Chinese biopharmaceutical firm Innovent Biologics 1801.HK and U.S. pharma giant Pfizer have struck a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12 early-stage cancer medicines, the companies said on Friday.
(Reporting by Sherin Sunny in Bengaluru; editing by Alan Barona)
Recent news on Innovent Biologics
See all newsChina emerges as obesity drug lab for Big Pharma
Eli Lilly becomes first drugmaker to have a GLP-1 weight-loss pill approved in China (updated)
China emerges as obesity drug lab for Big Pharma
Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results (updated)
Refile: Pfizer raises 2026 forecast on strong demand for blood thinner Eliquis